Viking Therapeutics’ Oral Obesity Drug Shows Promising 6.8% Weight Loss, Boosting Stock as Phase 1 Data Rolls Out
In the competitive arena of oral obesity treatments, Viking Therapeutics has made a strong showing with its obesity medication VK2735, ...
